Surgical resection followed by 6 months of systemic chemotherapy has been the mainstay of treatment for patients with resectable pancreatic cancer for many years, says Katz. Currently, the standard of care for these patients is pancreaticoduodenectomy or distal pancreatectomy followed by FOLFIRNOX. Watch here . . .
Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the utility of preoperative chemotherapy for patients with resectable pancreatic cancer.